leukotriene

Other new treatments block a cytokine or one kind of leukotriene.

Leukotriene modifiers are available in the United States only by prescription.

Leukotriene pathway modifiers are not used to treat asthma attacks.

This reduces the bronchoconstriction otherwise caused by the leukotriene and results in less inflammation.

Very little is known about this putative leukotriene.

Some doctors have succeeded with a class of asthma drug called leukotriene receptor antagonists.

Leukotriene modifiers sometimes cause side effects such as vomiting, diarrhea, and headaches.

Improved lung function compared with adding a leukotriene pathway modifier.

This is a low-affinity receptor for leukotrienes, especially leukotriene B4.

The mouse enzyme is specific for leukotriene C4.

It inhibits leukotriene synthesis to provide therapy in rheumatologic illness.

For instance, a drug that blocks one kind of leukotriene may prevent blocked airways but have no effect on itchy eyes.

Montelukast causes fewer side effects than other leukotriene pathway modifiers.

Rapid improvement of clinical manifestations and changes in neutrophil leukotriene profile.

By keeping these chemicals from producing swelling, leukotriene inhibitors reduce inflammation.

It is suggested that this compound exerts its activities through antagonism on leukotriene D4-induced responses.

Research shows that compared with a placebo, leukotriene pathway modifiers:

Another example of its use is in the synthesis of leukotriene A methyl ester.

Leukotriene C4 synthase deficiency is an inborn error of metabolism.

Leukotriene D4 is one of the leukotrienes.

Leukotriene pathway modifiers improve lung function and decrease asthma symptoms.

It has also been shown that flunoxaprofen inhibits leukotriene rather than prostaglandin synthesis.

Singulair blocks the leukotriene pathway in asthma and allergic rhinitis.

This is an Eicosanoid that inhibits leukotriene activity.

It is synthesized by leukotriene-A4 hydrolase from leukotriene A4.